-
2023-508670-28-00
5
2024-08-26
Hypertension
-
2022-502954-15-00
4
2024-06-21
Idiopathic pulmonary fibrosis
-
2023-506457-38-00
5
2024-06-05
Chronic kidney disease (CKD) and hypertension.
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-507685-10-00
5
2024-05-30
High-Risk Non-muscle-invasive Bladder Cancer
-
2023-508630-34-00
5
2024-05-28
Overweight
-
2023-508085-15-00
5
2024-05-15
Chronic Obstructive Pulmonary Disease
-
2023-503827-25-01
5
2024-02-16
Non-Small Cell Lung Cancer (NSCLC)
-
2023-503288-40-00
5
2024-01-26
Unresectable or Metastatic Melanoma
-
2023-503575-21-00
5
2024-01-23
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
-
2023-505023-31-00
5
2023-11-17
Renal cell carcinoma
-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2022-500802-16-00
5
2023-11-01
Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
-
2022-503004-24-00
5
2023-10-20
Influenza virus
-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2022-501419-15-00
5
2023-08-23
Atrial Fibrillation
-
2022-501176-26-00
5
2023-08-04
Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-501576-25-00
5
2023-07-07
Melanoma
-
2022-501352-28-00
5
2023-06-07
Severe community-acquired pneumonia (sCAP)
-
2022-501608-85-00
5
2023-05-09
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2022-501506-36-00
5
2023-04-11
First-line treatment of participants with metastatic nonsmall cell lun
-
2024-512890-28-00
5
2023-03-20
Primary immune thrombocytopenia (ITP)